Artiva Biotherapeutics (ARTV) Return on Capital Employed (2024 - 2026)

Artiva Biotherapeutics (ARTV) has 3 years of Return on Capital Employed data on file, last reported at 85.59% in Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 85.59%, down 4576.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 85.59% (down 4576.0% YoY), and the FY2025 annual result was 57.14%, down 1077.0% from the prior year.
• Return on Capital Employed fell to 85.59% in Q1 2026 per ARTV's latest filing, from 70.82% in the prior quarter.
• Over five years, Return on Capital Employed peaked at 26.44% in Q3 2024 and troughed at 85.59% in Q1 2026.
• A 3-year average of 51.68% and a median of 48.11% in 2025 frame the typical range for Return on Capital Employed.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 3176 bps in 2025, then sank 4576 bps in 2026.
• A 3-year view of Return on Capital Employed shows it stood at 32.77% in 2024, then plunged by 116 bps to 70.82% in 2025, then decreased by 21 bps to 85.59% in 2026.
• Business Quant data shows ARTV's Return on Capital Employed at 85.59% in Q1 2026, 70.82% in Q4 2025, and 58.2% in Q3 2025.